Augmenix

Category Archives

Augmenix Ranked as One of America’s Fastest-Growing Private Companies

Augmenix Ranked as One of America’s Fastest-Growing Private Companies With a Three-Year Sales Growth of 643%, Augmenix is one of the Fastest Growing Read more...

Augmenix raises $6m in Series E round

Augmenix said today it raised $6 million in a Series E round of funding to support the development of next-gen products and support the Read more...

Augmenix’ SpaceOAR® System Experiences Rapid U.S. Adoption

WALTHAM, Mass.--(Business Wire)--Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following Read more...

Augmenix Announces Publication of SpaceOAR® System Clinical Trial Results in Leading Radiation Oncology Journal

Pivotal Study Demonstrates Product Safety and Patient Benefits in Men Undergoing Prostate Radiotherapy WALTHAM, Mass.—Augmenix, Inc., a medical Read more...

Provision first proton therapy center using new product to benefit prostate cancer patients

KNOXVILLE, Tenn. (WVLT)-- Provision Center for Proton Therapy is helping pioneer a new product that will help further protect prostate cancer patients Read more...

New prostate treatment protects from radiation effects

CHARDON, Ohio -- Two days ago, the FDA approved a new product that protects prostate cancer patients from the side effects of radiation. It's called Read more...

Augmenix Announces Clearance of SpaceOAR® System

Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, today announced Read more...

Augmenix aims for profitability with $10.8M Series D round as Varian acquisition option expires

Protecting patients from unnecessary exposure to radiation is the aim of start-up Augmenix. To advance its efforts and achieve profitability, the company Read more...

Augmenix Announces Completion of Series D Financing

Augmenix Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy today announced Read more...

Augmenix Receives CE Mark Approval for TraceIT® Fiducial Marker and TraceIT® Gel System

Augmenix, Inc. today announced that it has received European commercial approval for both TraceIT Fiducial Marker and TraceIT Gel System, absorbable markers Read more...

Page 2 of 3123

Contact Info

info@catalysthealthventures.com

(781) 228-5228

50 Braintree Hill Office Park
Suite 301
Braintree, MA 02184